secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001193125-23-206247
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea Pharma Q2 net loss $28.2M; progresses COVID-19 & HCV trials
----------------------------------------------------------------

- Net loss of $28.2M in Q2 2023 (EPS -$0.34) compared to $31.3M loss in Q2 2022.
- Cash, equivalents and marketable securities $608.1M, down $38.6M from Dec 2022.
- Phase 3 SUNRISE-3 trial amended: eligibility broadened, target enrollment ~2,200; topline expected mid-2024.
- Phase 2 HCV study of bemnifosbuvir+ruzavir dosing; initial data from lead-in cohort (~60 pts) expected 4Q23.
- R&D expenses rose to $22.1M from $19.9M YoY, driven by trial costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312523206247/0001193125-23-206247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312523206247/d534379d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-206247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer